Pancreatic Cancer Biology
We interrogate core vulnerabilities of pancreatic ductal adenocarcinoma (PDAC) to enable precision therapeutics.
SPARK lab
Screening · POLQ · Antigen (neoantigen, biologics) · Repair (DDR) · KRAS
A pancreatic cancer research laboratory at Memorial Sloan Kettering Cancer Center (MSKCC), Manhattan, New York.
Research
DNA Damage Repair (DDR) and POLQ
We study error-prone end-joining pathways, polymerase theta (POLQ), and synthetic lethal interactions that can be exploited therapeutically.
KRAS-driven Vulnerabilities
We map KRAS-centric signaling and metabolic rewiring to reveal tractable intervention points in PDAC.
Neoantigens and Biologics
We develop pipelines for neoantigen discovery and biologic modalities to target tumor-specific epitopes.
High-throughput Screening
We deploy genetic and small-molecule screens to identify combination strategies and resistance mechanisms.
People
🧪
Principal Investigator — Wungki Park, MD, MS
Gastrointestinal Medical Oncologist at MSKCC, leading translational efforts bridging mechanistic insights to clinical impact.
🔬
Postdoctoral Fellows
Driving discovery across DDR, KRAS signaling, and immuno-oncology.
🧫
Students & Staff
Engineering assays, models, and datasets for robust reproducible science.
Publications
- Selected works on DDR, POLQ, KRAS vulnerabilities, and neoantigen discovery. Full list coming soon.
News
- We are recruiting! Reach out if you are passionate about PDAC research.